Dr. Martens plc (LON:DOCS - Get Free Report) insider Jon Mortimore bought 159 shares of the firm's stock in a transaction on Thursday, April 11th. The stock was purchased at an average price of GBX 94 ($1.19) per share, with a total value of £149.46 ($189.17).
Dr. Martens Trading Down 2.0 %
Shares of DOCS traded down GBX 1.95 ($0.02) during midday trading on Friday, hitting GBX 94 ($1.19). The stock had a trading volume of 648,371 shares, compared to its average volume of 1,217,067. Dr. Martens plc has a fifty-two week low of GBX 72.25 ($0.91) and a fifty-two week high of GBX 174.70 ($2.21). The business has a 50-day simple moving average of GBX 91.21 and a two-hundred day simple moving average of GBX 100.17. The firm has a market cap of £904.14 million, a P/E ratio of 940.00, a price-to-earnings-growth ratio of 2.70 and a beta of -0.02. The company has a current ratio of 2.44, a quick ratio of 1.13 and a debt-to-equity ratio of 143.48.
Dr. Martens Cuts Dividend
The business also recently declared a dividend, which was paid on Friday, February 2nd. Investors of record on Thursday, January 4th were issued a dividend of GBX 1.56 ($0.02) per share. This represents a dividend yield of 1.36%. The ex-dividend date of this dividend was Thursday, January 4th. Dr. Martens's dividend payout ratio is currently 6,000.00%.
Dr. Martens Company Profile
(
Get Free Report)
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It offers originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.
Featured Articles
Before you consider Dr. Martens, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.
While Dr. Martens currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
